Invention Grant
- Patent Title: Bispecific antibodies against CD3ϵ and BCMA
-
Application No.: US15501620Application Date: 2015-08-03
-
Publication No.: US10253104B2Publication Date: 2019-04-09
- Inventor: Minh Diem Vu , Klaus Strein , Oliver Ast , Marina Bacac , Lydia Jasmin Hanisch , Tanja Fauti , Anne Freimoser-Grundschober , Ralf Hosse , Christian Klein , Ekkehard Moessner , Samuel Moser , Ramona Murr , Pablo Umana , Sabine Jung-Imhof , Stefan Klostermann , Michael Molhoj , Joerg Regula , Wolfgang Schaefer
- Applicant: ENGMAB AG
- Applicant Address: CH Wilen
- Assignee: ENGMAB AG
- Current Assignee: ENGMAB AG
- Current Assignee Address: CH Wilen
- Agency: Eckert Seamas Cherin & Mellot, LLC
- Agent Patrick H. Higgins
- Priority: EP14179705 20140804
- International Application: PCT/EP2015/067841 WO 20150803
- International Announcement: WO2016/020332 WO 20160211
- Main IPC: C07K16/00
- IPC: C07K16/00 ; C07K16/28 ; C07K16/46 ; C07K16/30 ; A61K39/00

Abstract:
A bispecific bi- or trivalent antibody specifically binding to the two targets which are extracellular domain of human B cell maturation antigen (BCMA) and human CD3ε, wherein the variable domains VL and VH in a light chain and the respective heavy chain are replaced by each other, characterized in comprising a constant domain CL wherein the amino acid at position 124 is substituted independently by lysine (K), arginine (R) or histidine (H) (numbering according to Kabat), and in the respective constant domain CH1 the amino acid at position 147 and the amino acid at position 213 is substituted independently by glutamic acid (E), or aspartic acid (D) (numbering according to EU index of Kabat). Also the manufacture and use of said antibody.
Public/Granted literature
- US20170306036A1 BISPECIFIC ANTIBODIES AGAINST CD3EPSILON AND BCMA Public/Granted day:2017-10-26
Information query